ReviewFrontiers in pharmacology2026
Lateral hypothalamic orexinergic neurons as central mediators of pain modulation and non-pharmacological analgesia.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Olfactory Piriform Cortex-Lateral Hypothalamus Neural Circuit Contributes to Linalool-Induced Analgesia.CNS neuroscience & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pain is a complex sensory and affective experience regulated by distributed neural circuits that integrate internal physiological states with external stimuli. Orexinergic neurons, a widely projecting neuronal population within the lateral hypothalamus (LH), play a central role in this process. This review synthesizes current evidence on the involvement of LH orexinergic neurons in nociceptive regulation and highlights their role as a key integrative substrate for non-pharmacological analgesia. Orexin peptides (orexin A and orexin B) modulate both the sensory-discriminative and affective-motivational components of pain via their receptors (OX1R and OX2R) in a context-dependent manner, producing antinociceptive or pro-nociceptive effects depending on peptide subtype, receptor distribution, circuit architecture, and pain modality. In parallel, emerging evidence indicates that orexinergic neurons are critically engaged in diverse non-pharmacological analgesic paradigms, including stress-induced analgesia, olfactory modulation, electroacupuncture, and exercise-induced hypoalgesia. In addition, other neuronal populations within the LH, such as glutamatergic, GABAergic, and neurotensinergic neurons, also contribute to pain regulation in a circuit-specific manner and partially overlap anatomically and functionally with orexinergic neurons. Collectively, these findings position LH orexinergic neurons as a central node linking neural circuit dynamics with the behavioral and physiological modulation of pain. Targeting orexin-related pathways may therefore provide novel avenues for the development of non-pharmacological and integrative pain management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.